Case Study

Accelerating SARS-CoV-2 Immunotherapy Speed To Clinic With Pre-Made Process Liquids

Lab of the Future GettyImages-1449925917

A clinical-stage biotherapeutics company developing a COVID-19 immunotherapy faced difficulties in scaling up its manufacturing operations due to limited resources. To solve this issue, the company outsourced the production of ten different buffers to a chemical supplier. The company's previous chemical supplier presented problems with delayed communications specifically regarding lead time issues and any small volume requests from the supplier. To overcome these problems, the company collaborated with Thermo Fisher Scientific, who supplied pre-made process liquids for use in manufacturing. This partnership resulted in significant annual cost savings and a 36% reduction in lead times, allowing the biotherapeutics company to concentrate on its primary goal of speeding up SARS-CoV-2 immunotherapy development.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online